She is told to take two ibuprofen an hour before arriving and to expect something like period cramps. Within minutes of the camera entering her cervix, she is gripping the edge of the bed, and somewhere in the middle of the procedure she stops being able to say so. This is not a rare account. It is the modal experience for a meaningful share of the women who undergo outpatient hysteroscopy each year, and the fact that it has taken this long to become a matter of institutional concern says as much about the NHS's incentive structures as it does about individual clinicians.
Outpatient hysteroscopy exists because it works, in the narrow sense that matters to a system under sustained productivity pressure. It avoids general anaesthetic lists, it recovers faster, and it moves more patients through in a day than theatre-based alternatives ever could. Under Sir Jim Mackey's tenure, with ICBs consolidating and budgets tightening further, that arithmetic has only become more attractive to trust finance directors. None of this is illegitimate. The problem is what has been allowed to travel alongside it unexamined: an assumption, never quite stated but consistently acted on, that patient distress during the procedure is a cost the system can absorb rather than a signal it must respond to.
The Royal College of Obstetricians and Gynaecologists' own data undercuts the "mild cramping" framing that still shapes what women are told beforehand. A third reporting pain at seven out of ten or higher is not a tail-end outcome. It is a routine one, and guidance already exists instructing clinicians to stop and reschedule under proper sedation when pain becomes unbearable. That guidance is not being followed with any consistency, according to those tracking outcomes, which turns this from a clinical judgement question into a governance one. A protocol that is written down but not enforced is not a safeguard. It is a liability sitting quietly on a trust's risk register until someone brings a claim.
That liability is sharpened by the consent problem sitting underneath it. Women are rarely offered a structured choice between local anaesthetic, conscious sedation or general anaesthetic before the appointment is booked. They are handed a painkiller regimen and a time slot. Whatever the clinical merits of outpatient management, consent obtained on the basis of "mild cramping" when a third of patients will experience the opposite is consent obtained on a false premise. Trusts have spent the past several years absorbing hard lessons from Ockenden and the Amos review about what happens when patient testimony is heard late and acted on later. Hysteroscopy looks like the same failure mode recurring somewhere less dramatic, which is precisely why it has been easier to ignore.
This is also where the Women's Health Strategy and the government's 10-Year Health Plan face a genuine test of whether their language converts into practice. Both documents invoke exactly this kind of ordinary, high-volume procedure as proof that listening to women changes clinical behaviour rather than communications strategy. Hysteroscopy is a useful test precisely because the fix is not expensive. It requires no new equipment, no additional workforce, and no capital bid. It requires trusts to build a pre-procedure conversation about pain relief options into a pathway that currently omits it, and it requires commissioners to check that this happens rather than assume it does.
Campaigners have reached for the language of medical misogyny, and there is a case to be made for it. But the more durable argument for NHS leaders is narrower and harder to dismiss. A system that has spent four years telling women it has learned from its maternity failures cannot allow a routine gynaecological procedure to run on informed consent that quietly isn't informed. If that gap persists once the evidence is this clear, it will not read as an oversight. It will read as a choice.
